Likvor presents revolutionary technology

Press release 
September 17, 2008


Likvor presents revolutionary technology

LinkMed's portfolio company Likvor AB is presenting revolutionary technology,
that facilitates better and a more accurate diagnosis of idiopathic Normal
Pressure Hydrocephalus, at the international Hydrocephalus 2008 congress in
Hanover, September 17- 20. The technology can help patients suffering from
dementia, balance and gait disturbances to go back to normal life. The
instrument can also be used to control whether or not a shunt implant is
functioning properly.

Normal Pressure Hydrocephalus (NPH) is a neurological condition caused by
disturbances in the cerebrospinal fluid (CSF) found in the cavity of the brain
and spinal cord canal. The main clinical features of NPH are balance and gait
disturbances, dementia and urinary incontinence. The most common form of NPH is
Idiopathic Normal Pressure Hydrocephalus (INPH), which is primarily found in
elderly patients and is often incorrectly diagnosed as Alzheimer's or
Parkinson's disease. INPH is a potentially reversible disorder, which means that
patients who receive the correct diagnosis and treatment can return to normal
life. The condition can be treated by surgically implanting a shunt into the
brain to regulate CSF pressure and flow.

More secure diagnosis
Likvor's tool is the is first commercially available instrument that can safely
and successfully measure the pressure, flow and conductance of CSF. The tool
will facilitate the diagnosis of INPH and control whether the shunt implant
functionality. The technology behind Likvor's tool is based on more than 30
years of clinical research at Norrland's University Hospital and Umeå
University. Likvor's instrument is currently being tested in an independent
multicenter trial at six university hospitals in the Nordic region.  

Large market
The calculation of INPH patient volume is based on the prevalence of dementia.
It is estimated that around 9 percent of the population over 65 years of age
suffer from dementia and of these up to 10 percent in actual fact suffering from
INPH.  In Europe, North America and Japan this is equivalent to around 1.4
million people. Likvor's tool enables patients to be correctly diagnosed and
thereby receive the right treatment, resulting in great benefits primarily for
the patient but also for society. 

Hydrocephalus 2008 (www.hydrocephalus2008.com) is the main international
congress in this scientific field, which this year is being held in Hanover from
September 17-20. Likvor's tool will be CE marked in autumn 2008 and will be
available on the market from the beginning of 2009. Likvor AB was established in
early 2007 at which time the company acquired all the rights to the instrument
as well as related patents from the researchers behind the technology.  Likvor's
principal owners are Uminova Invest and LinkMed, both with 49 percent of share
capital. For more information about Likvor visit www.likvor.com.



For more information contact:
Kjell Öberg, CEO Likvor
tel. +46 90 15 48 94

Okee Williams, Portfolio Manager LinkMed, 
tel. +46 8 508 93 940 




LinkMed, in collaboration with innovators, develops new life science companies.
By contributing entrepreneurship and capital, LinkMed has created a portfolio of
twelve companies, seven in biotechnology and five in medical technology. The
company's principal owners are FastPartner, Koncentra Holding, and the founder
Ingemar Lagerlöf. The LinkMed share is listed on the OMX Nordic Exchange
Stockholm in the small-cap sector (ticker:LMED).